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Abstract
There are only few reviews concerning visceral aneurysms in cirrhotics, and a small number of papers on visceral aneurysms
in liver transplant patients. The present paper investigates this condition in both groups of patients in a 10-year-
retrospective study.
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Introduction
Visceral aneurysms are rare in the general population
(rate,0.2%) [1]. Their detection lies between 7% and 50% of
patients with liver cirrhosis [2–3]. The average age of occurrence
varies from 49 [4] to 66 years [5]. Visceral aneurysms and
pseudoaneurysms after liver transplantation (LT) represent a rare
disease but the overall number of studied liver transplanted
patients so far is very small. A review of the literature enabled us to
identify approximately 60 post-transplant pseudoaneurysms of the
hepatic artery (HA) and 7 splenic artery (SA) aneurysms [6–7–8–
9–10], with an incidence estimated to be about 0.3–1% [6].
The aim of this study is to examine separately the visceral
aneurysms and pseudoaneurysms treated in our unit over the past
10 years in two different groups of patients: patients with end-stage
liver diseases – considered as representatives of patients with
cirrhosis, even though at an advanced stage - and patients who
underwent a LT.
Starting with a review of the published literature on this subject,
we tried to identify the actual prevalence of visceral aneurysms and
pseudoaneurysms, the possible causes of their development in
these two groups of patients, and their correct treatment.
Methods
Step One: pre-transplant patients
As inclusion criteria we considered all consecutive adult patients
with cirrhosis who underwent LT in our unit from January 2000 to
November 2010 (n= 302); in these patients we calculated the pre-
LT incidence of visceral aneurysms.
At the end, we included in this study only patients with
hepatocellular cirrhosis with or without cancer and cholestatic
cirrhosis. Patients with fulminant liver failure or other indications
for LT, were excluded.
In these patients we attempted to identify potential common
factors related to the occurrence of such aneurysms. For this part
of the study, 3 further patients who underwent LT in 1995, 1996
and 1999 were considered. These 3 patients were not considered
for the incidence of aneurysms, but they were for the study of the
risk factors. Therefore 305 cases were studied. Among continuous
variables there were: patient age, biochemical data (recorded at
the time of transplantation) including serum Aspartate amino-
transferase (AST), Alanine aminotransferase (ALT), Total Biliru-
bin, Creatinine, gamma -Glutamyltransferase (GGT), amylase,
International Normalized Ratio (INR), blood platelets, AST
platelet ratio index (A.P.R.I.) and Mayo End-Stage Liver Disease
(MELD) Scores, and the longitudinal diameter of the spleen
measured with the US scan.
Among categorical data, in addition to the epidemiological
variables such as age and sex, we considered factors related to
arterial and portal hypertension: we therefore evaluated the
recipient gender, the presence in the medical history of previous
surgery or a TACE (transarterial chemo-embolization), arterial
hypertension, antihypertensive therapy, beta-blocker therapy,
oesophageal varices, the type of liver disease, and the type of
viral liver disease (hepatitis B and C).
Step Two: post-transplant patients
We considered the visceral aneurysms and pseudoaneurysms in
adult patients after the first LT. The LT itself was considered the
main inclusion criteria for this part of the study, indipendently of
the primary patology. Retransplantations and patients with known
pre-LT aneurysms were excluded from the analysis. Therefore,
331 patients, transplanted from January 2000 to November 2010,
were included in the study. The mean follow-up period was
3,963,1 years. The patients underwent abdominal US scan on the
1st postoperative day and after that twice a week for the first month
and then during the outpatient clinic appointments whose
frequency decreased over time. However the US scan was
performed whenever needed according to the clinical picture.
The control CT scan was performed one month after surgery and
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after that whenever needed. The late-follow-up appointments were
scheduled twice a year. No patients were lost during the follow up.
Variables of liver donors, recipients and transplantations, possibly
related to the onset of aneurysms and pseudoaneurysms, were
identified. In this analysis we included also two cases of aneurysms
that occurred in the post-transplant period just prior to the stated
analysis (LT 315 and 444).
The variables analyzed in the 333 patients were as follows:
continuous data including the donor’s age, GGT, the recipient’s
age, biochemical data (recorded at the time of transplantation) –
AST, ALT, total bilirubin, creatinine, GGT, amylase, platelets,
INR –, the MELD score, the pre-LT longitudinal diameter of
spleen detected on US scan, and the total ischemia time during
transplantation.
Among categorical data, we considered the donor’s and
recipient’s gender, the presence in the medical history of a
previous surgery, TACE (transarterial chemo-embolization), pre-
LT arterial hypertension, antihypertensive therapy, beta-blocker
therapy, and oesophageal varices, the onset of pre-LT aneurysms,
the type of liver disease and of viral liver disease (hepatitis B and/
or C), the type of liver grafts (whole/partial), the performance of
complex vascular reconstructions during the transplantation.
The study was approved by the Ethics Committee of the
Institution where data were collected.
Informed consent was obtained as usual for medical, surgical,
radiological treatments, not specifically for this retrospective study.
Patients gave written consent for every procedure performed in the
hospital including treatment of data for medical purposes.
Statistical Analysis
In both steps we performed univariate analyses with the
Student’s t-test or x2 test, whenever appropriate. We calculated
the odds ratio (OR) and 95% confidence intervals (95% CI) of
aneurysm using multivariate logistic models including variables
that were significant on univariate analyses or were considered
important in literature.
P#0,1 was considered significant in the univariate analyses and
#0.05 in the multivariate.




Eight (2.6%) out of 302 end-stage chronic liver disease patients
who underwent LT between 2000 and 2010 were identified as
affected with visceral aneurysms before LT. Among the 3 patients
added in the clinical analysis there was one patient with a pre-LT
aneurysm (LT 272). Therefore, a total of 9 aneurysms were
included in the clinical analysis, outside the calculation of
incidence. Among cirrhotic, cholestatic and cancer (in cirrhosis)
patients we observed 4 (2,3%), 1 (3,7%) and 3 (2,8%) aneurysms
respectively.
There were 172 patients (56,4%) with cirrhosis caused by
different pathologies, 27 patients (8,9%) with cholestatic cirrhosis
and 106 patients (34,8%) with hepatocarcinomas in cirrhosis.
Males were 212 (69,5%), females 93 (30,5%).
In all 9 cases, the aneurysms were located in the distal segment
of the SA, and in one case also in the middle one. In 4 patients
aneurysms were multiple, in 5 single. The diameter of the
aneurysms was between 1.5 and 3 cm.
At univariate analysis of continuous data, longitudinal diameter
of spleen (p= 0.06) and hyperamylasemia (p= 0.017) were
significantly higher in patients with aneurysms (Table 1). Cate-
gorical data showed statistical significance in the female group
(odds ratio 2.9, p = 0.09), in the b-blocker therapy group (odds
ratio 4.6, p = 0.015) and in the pre-LT TACE group (odds ratio
6.5, p = 0.017) (Table 2).
The multivariate analysis (Table 3) showed elevated ORs in the
b-blocker therapy group, increased amylase group and pre-LT
TACE group.
Splenic aneurysms in cirrhotic patients were always asymptom-
atic. No spontaneous pre-LT aneurysm rupture was observed. The
diagnosis of aneurysm in these patients was always made with CT
scan during the pre-LT study.
Four patients (44%) underwent a proximal SA ligation during
LT (in 1 case the proximal stump of the SA was used for the
anastomosis with the common HA of the donor).
Five patients (55%) underwent splenectomy as treatment for
splenic aneurysm, and in particular three during LT.
In a fourth patient no treatment could be performed during LT
and a postoperative embolization of the SA failed; a splenectomy
Table 1. Univariate analysis of continuous variables among cirrhotics waiting for LT, with and without visceral aneurysms.
continuous variables Cirrhotics with visceral aneurysms Cirrhotics without visceral aneurysms
N mean±SD n Mean±SD p
Age (years) 9 50610 296 5169 0,83
Total Bilirubin (mg/dl) 9 2,361,5 288 569,5 0,38
Creatinine (mf/dl) 9 0,760,3 269 160,7 0,30
INR 9 1,260,2 283 1,360,4 0,62
MELD Score 9 1263 267 1365 0,42
PLT (n/mm3) 8 56.000622.017 253 82.620651.226 0,12
Bipolar diameter of the spleen(cm.) 7 19,761,2 280 16,864 0,06
ALT (UI/L) 9 53652 252 796112 0,49
AST (UI/L) 9 69654 252 986144 0,55
GGT (UI/L) 9 55642 237 88687 0,26
Amylases (IU/L) 8 127688 185 64671 0,017
A.P.R.I. 9 3,863,9 252 4,9612 0,81
doi:10.1371/journal.pone.0029544.t001
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was performed 2 months later. In a fifth patient an urgent post LT
splenectomy was required for ruptured aneurysm.
Post-transplant patients
We examined 331 patients who underwent consecutive LTs
from January 2000 to November 2010: 223 were males (67.4%)
and 108 (32.6%) females, the average age was 50.5610 years; the
follow-up period was 3.963.1 years.
Causes of LT were: mixed cirrhosis in 170 (51.3%), cholestatic
cirrhosis in 26 (7.8%), hepatocarcinoma in cirrhosis in 109
(32.9%), fulminant hepatic failure in 15 (4.5%), and other
disorders in 11 (3.3%).
Visceral aneurysms and pseudoaneurysms were detected in 6
patients (1.8%). Two additional patients with post-LT aneurysms
identified just before the study period (one case in 1996, the other
in 1999) were included only for the statistical analysis of
aetiopathogenetic variables. Consequently, the total number of
patients affected by aneurysms and pseudoaneurysms in the
postoperative period was 8: there were 5 SA aneurysms and 3
pseudoaneurysms of the HA.
Aneurysms occurred in 4 patients (2,3%) with mixed cirrhosis, 1
patient (3,8%) with cholestatic cirrhosis, 2 patients (1,8%) with
hepatocarcinoma, and 1 patient (9%) with other disorders (a case
of Budd-Chiari Syndrome).
In univariate analysis (Table 4–5), only the female group
reached statistical significance (OR 3.5 – 95% CI 0,83–15,1,
p = 0.06).
Among the 8 patients with an aneurysm after the first LT, 4
(50%) were asymptomatic, 3 out of 5 patients (60%) with SA
aneurysms, and 1 out of 3 (33%) with involvement of the HA.
Symptomatic patients
Two symptomatic splenic aneurysms presented with an abrupt
onset of hemorrhagic shock 5 and 8 days after LT: one patient
underwent an urgent splenectomy and he is still alive and in good





Cat.Variables categories N n % n % P
Rec. Gender M 305 4 44,4 208 70,3 0,09
F 5 55,6 88 29,7
surgery pre-LT yes 292 0 0 16 5,7 0,46
no 9 100 267 94,3
TACE yes 287 2 33,3 20 7,1 0,01
no 4 66,7 261 92,9
HTA yes 278 1 11,1 29 10,8 0,97
no 8 88,9 240 89,2
anti-HTA Treatment yes 278 1 11,1 22 8,2 0,75
no 8 88,9 247 91,8
b-block. therapy yes 292 5 55,6 60 21,2 0,01
no 4 44,4 223 78,8
Oesophageal varices no 283 3 75 99 35,5 0,25
F1 1 25 151 54,1
F2 0 0 0 0
F3 0 0 29 10,4
Hepatic diseases cirrhosis 305 4 44,4 168 56,8 0,76
cholestatic 1 11,1 26 8,8
neoplastic 4 44,4 102 34,5
HCV yes 305 5 55,6 146 49,3 0,71
no 4 44,5 150 50,7
HBV yes 305 4 44,5 89 30,1 0,35
no 5 55,6 207 69,9
Viral diseases (HCV/HBV) yes 305 8 88,9 222 75 0,34
no 1 11,1 74 25
doi:10.1371/journal.pone.0029544.t002
Table 3. Risk of pre-LT aneurisms among cirrhotics waiting
fort LT transplant.
ODDS
RATIO 95% CI P
TACE 11,76 1,46 – 94,4 0,02
b-block. therapy 7,49 0,98 – 57,7 0,05
Amylases (x 100) 1,95 1,07 – 3,56 0,02
Results of a multivariate logistic regression.
doi:10.1371/journal.pone.0029544.t003
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conditions; the second one died. One of the two symptomatic HA
psudoaneurysms presented with an episode of hemobilia 56 days
after transplantation, while the second had a severe deterioration
in biochemical markers of liver function on the 12th postoperative
day.
Overall, the symptoms of visceral symptomatic aneurysms
appeared after a mean time of 19627 days after LT, whereas the
median time was 9 days after LT; In conclusion, in our experience,
the symptoms of such aneurysms appear very early after LT.
Asymptomatic patients
The visceral aneurysms were discovered incidentally with CT
scans performed for other reasons, after 18,362 months, with a
median time of 2,9 months.
An incidental diagnosis was performed with CT scan in 4 cases.
Intraoperative diagnosis was made in 2 patients with haemor-
rhagic shock. In 2 patients there was time to perform US scan, CT
scan and arteriography and after that elective surgery could be
performed.
With regard to the therapy, among 5 splenic aneurysms, 2 had
no treatment (LT 813-839) – in one patient the SA had already
been ligated at LT, in order to improve the HA flow; 3 underwent
splenectomy, an unsuccessful laparotomy and a distal splenopan-
createctomy with construction of an hepato-aortic conduit – 5, 8
and 21 days after LT respectively (LT 744, 315 e 806).
Among 3 patients with HA aneurysms, one of them (LT 543) –
affected by an intrahepatic aneurysm and an aneurysm of a
previous aorto-hepatic conduit – underwent a re-transplantation
with total hepatectomy and partial resection of the conduit with a
new arterial anastomosis. The patient died 2 years later for HCV
recurrence. The others (LT 731 and 444) underwent a resection
and an extra-anatomical HA reconstruction with an aorto-hepatic
conduit. Both of them are still alive and in good conditions.
Symptomatic and asymptomatic SA complications appeared
after a mean (average) time of 40656 days after LT (median 32),
while those of the HA after 23637 months (median 23 months).
However, sympomatic aneurysms appeared early: 5 and 8 days
after LT for ruptured SA aneurysms, and 10 and 56 days after LT
for HA pseudoaneurysms.
Overall, only one (12,5%) out of 8 patients after LT died of
causes directly related to a ruptured visceral aneurysm.
Discussion
This study considers separately two specific categories of
patients:
1) liver transplant candidates, i.e. end-stage liver disease
patients, a subclass of severe liver disease patients. Patients
with liver disease but not suitable for LT were not evaluated
in this study.
2) liver transplanted patients, rarely studied in non-transplant
units.
The aim is not to compare those two groups but to add data
concerning visceral aneurysms in these two distinct populations.
1) Pre-transplant patients
The incidence of visceral aneurysms in our patients with severe
cirrhosis was quite small (2.6%), This rate is probably realistic, if
we consider the autopsy data for the general population (0.2 to
0.8%) [9–10] and the different data reported in previous studies on
patients with cirrhosis (7–50%) [1–2]. Probably in our study some
aneurysms were missed- frequently in cirrhotic patients the SA is
long and tortuous and it may mask some small aneurysms. -
anyway rates over 10% seem too high.
SA aneurysms occurred only in cirrhotic patients (9 of 9, i.e.
100%). This is consistent with published observations [11].
The analysis of etiological factors provided interesting informa-
tion despite the limited number of aneurysms, considering that
Table 4. Univariate analysis of continuous variables (just before LT) of transplanted patients, according to the presence of post-LT
visceral aneurysms.
CONTINUOUS VARIABLES (t-test) at LT
PATIENTS W POST_LT ANEURYSMS PATIENTS W/O ANEURYSMS
n Mean6SD n Mean6SD p
D. Age (years) 8 46622 324 50618 0,58
D. GGT (IU/L) 8 49674 282 47670 0,93
Total ischemia time (min.) 8 5156115 324 5126107 0,94
R. Age (years) 8 45614 325 50610 0,19
R. Total Bil.
irubin (mg/dL)
8 5,265,8 315 5,5610,2 0,93
R. Creatinine (mg/dL) 7 0,760,3 295 1,160,9 0,31
R. INR 8 1,460,2 310 1,460,6 0,90
R. MELD 6 1263 294 1466 0,46
R. PLT (n/mm3) 7 89.285693.679 278 86.126654.301 0,88
R. spleen bipolar diameter(cm.) 5 1763 305 1664 0,61
R. ALT (IU/L) 7 78651 277 1336347 0,67
R. AST (IU/L) 7 82641 277 1346335 0,68
R. GGT (IU/L) 7 58646 258 88686 0,35
R. Amylases (IU/L) 6 84666 203 66671 0,55
doi:10.1371/journal.pone.0029544.t004
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most of the articles appeared in literature included no more than
20 cases each [12,13].
The female gender was more likely to be affected by aneurysms,
with an odds ratio of 2.9 at univariate analysis. Although the
female predominance was not significant at multivariate analysis;
this trend is consistently reported in literature [14]. The reason
maybe linked to the structural components of the arteries and to
the effect of estrogens during pregnancy or during the menstrual
cycle on the elastic tunica of the vascular wall [15].
The longitudinal diameter of the spleen was a significant risk
factor at the univariate analysis but not at the multivariate one.
The figure appears to be related to the severity of portal
hypertension and its hemodynamic changes [3–16–17–18–19].
The absence of statistically significant relations at univariate
analysis with liver function or specific scores (transaminases, INR,
MELD and A.P.R.I. Scores) suggests that there is no evident
relationship between liver function, hemodynamic changes and
aneurysms’ onset.







categories N n % n % p
D Gender M 322 5 62,5 157 50 0,48
F 3 37,5 157 50
Rec Gender M 333 3 37,5 221 68 0,06
F 5 62,5 104 32
pre-LT Surgery Y 317 1 12,5 16 5,2 0,36
N 7 87,5 293 94,8
pre-LT TACE Y 313 1 16,7 22 7,2 0,37
N 5 83,3 285 92,8
pre-LT HTA Y 303 1 12,5 33 11,2 0,90
N 7 87,5 262 88,8
pre-LT anti-HTA treatment Y 303 1 12,5 26 8,8 0,71
N 7 87,5 269 91,2
pre-LT anti-b-blocK. treatment Y 1 12,5 65 21 0,55
N 7 87,5 244 79
oesophageal varices N 309 3 100 107 35 0,06
F1 0 0 167 54,6
F2 0 0 0 0
F3 0 0 32 10,5
Pre-LT Aneurysms Y 333 1 12,5 7 2,2 0,05
N 7 87,5 318 97,8
Hepatic diseases cirrhosis 333 4 50 167 51,4 0,58
colestatic 1 12,5 26 8
neoplastic 2 25 107 32,9
fulminant 0 0 15 4,6
others 1 12,5 10 3,1
HCV Y 333 3 37,5 148 45,5 0,65
N 5 62,5 177 54,5
HBV Y 333 3 37,5 86 29,5 0,62
N 5 62,5 229 70,5
Viral diseases (HCV/HBV) Y 333 6 75 230 70,8 0,79
N 2 25 95 29,2
Transplanted Liver whole 333 7 87,5 282 86,8 0,95
partial 1 12,5 43 13,2
Arterial Reconstructions Y 333 2 25 52 16 0,49
N 6 75 273 84
doi:10.1371/journal.pone.0029544.t005
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The absence of a relation between HBV and HCV infections
and the onset of aneurysms suggests that the hemodynamic
changes induced by cirrhosis are independent of the etiology. The
data reported by some authors [14–20] of an increased prevalence
of HBV positive patients were probably biased by heterogeneity of
patients undergoing LT.
Multivariate analysis of factors believed to be related to the
onset of visceral aneurysms in patients with cirrhosis showed a
statistical significance for pre-transplant values of amylase, a
previous beta-blocker therapy and TACE.
Hyperamylasaemia could be related with mild pancreatitis
which could cause vascular damage and weakening of the SA [21–
22]. This finding has already been observed in other studies [13].
The beta-blocker therapy could also have some explanations:
first of all the beta-blockers are given to patients with the worst
portal hypertension; in addition the visceral vasodilatation induced
by beta-blockers might not be enough to balance the increased
visceral blood flow. The relationship with the Trans-arterial
chemo-embolization (TACE) is less clear: these treatments affect
the HA and its branches, so a relationship with the splenic
aneurysm of our cirrhotic population is unclear. This may be due
to vasospasm, induced by intra-arterial catheters, and increasing
the SA wall stress with increased risk of aneurysm formation.
In conclusion, factors such as levels of amylase, previous beta-
blocker therapy and TACE, need additional studies to confirm
their importance.
As reported in literature [23], visceral aneurysms are generally
asymptomatic. This observation was confirmed in our series.
Notably, SA aneurysms of our cirrhotic patients were always
asymptomatic.
According to the literature (24), angiography, that may be
diagnostic as well as interventional, is the best way to diagnose a
SA aneurysm (28). US scan has a low sensitivity while two-
dimensional and three-dimensional CT scan and MRI scan have a
better accuracy (6, 12, 26, 25). Aneurysms in our patients with
cirrhosis were always detected with CT scan during the pre-
transplant study. When CT scan revealed an aneurysm, this
finding was confirmed by arteriography. In this study US scan,
even with contrast (27), was more useful in HA abnormalities than
in SA aneurysms.
The transplant factor influences the classic therapeutic approach of
aneurysms in patients in waiting list for LT. Because of their small
diameter (never more than 3 cm) and consequently the low risk of
rupture, for fear of future adhesions or impairment of a vessel (the SA)
which could be useful at the time of transplantation, the treatment of
aneurysms is postponed until the moment of transplantation.
Consequently, at that time, a splenectomy is needed [28]. If the
splenectomy is difficult to be performed, as often happens, a proximal
SA ligation is chosen; however, this procedure may be unsatisfactory:
indeed, subsequent CT scans often show patency of these arteries not
likely related to splenic vascular recanalization, but to retrograde flow
from short gastric vessels; so a proximal and distal SA ligation should
be preferred [29-9-3-4-5-9-35]
With regard to radiological procedures, in our hospital there is
no such expertise to enable the use of arterial stents [30–31].
According to the literature, percutaneous endovascular-stent
placement for visceral aneurysms seems a promising procedure
but it is still anecdotal for HA and SA aneurysms (32, 33, 34);
moreover, arterial embolization often provides only partial success
and the problem of gastric recanalization remains.
2) Post-transplant patients
The rate of visceral aneurysms and pseudoaneurysms was 1.8%,
which is similar, although marginally lower than other published
series [6]. The aneurysms mainly affected the SA (5 out of 8, ie
62,5%), but 37,5% of cases involved the HA. This could stem from
the arterial anastomosis of the transplant, and not from a purely
hemodynamic disorder [6–11].
The analysis of risk factors registered only an increased
prevalence in females (OR 3.5), a fact that can be explained with
the same considerations previously reported concerning cirrhotic
patients. No other statistically significant factors were found; the
arterial reconstructions during the transplant, even if followed by
increased risk of aneurysmal lesions (odds ratio 1.85), did not reach
statistical significance.
Probably the variables considered for the study of transplanted
recipients – including some information of the donor and graft –
are inadequate to find a relation with the occurrence of aneurysms
after transplantation. Certain surgical factors such as, for example,
the type of liver used (whole or reduced) [12–35], and the
execution of vascular reconstructions during transplantation,
showed no statistically significant values as etiological factors in
transplanted patients (Table 2). Some factors, as re-transplant, and
biliary procedures, showed no significance, differently from other
reported results [6–35–36–37]. HA pseudoaneurysms surely must
have a difficult to identify technical explanation; for SA aneurysms
factors such as peaks of arterial pressure or the use of amynes
should be further investigated.
The clinical picture of transplanted patients was definitely
different from that of cirrhotics. Among the 8 transplanted
patients, four cases 260% of SA aneurysms and 33% of liver -
were asymptomatic. An acute rupture occurred in 2 cases of SA
aneurysms, that is in 25% of post-LT aneurysms, and in 40% of
post-LT spleen aneurysms [6–21].
In contrast to the data from cirrhotic patients, in transplanted
patients an incidental diagnosis occurred in only 50% of cases (4
patients).
Therapeutic procedures of post-LT aneurysms are complex. For
SA aneurysms we have usually followed the classic pattern of
laparotomy in case of emergency; the indication for radiological
procedures in semi-elective or elective conditions should probably
be increased. However, HA aneurysms always raise complex
surgical problems that can only be handled by experienced
surgeons: the construction of aorto-hepatic conduits is one of the
most common treatment options [6]; in case of treatment failure,
in contrast with splenic aneurysms, the consequence is an hepatic
graft with no arterial flow, a condition leading to death or
requiring re-transplantation.
Conclusion
Visceral aneurysms represent a poorly studied clinical entity with
only small series of observations in healthy subjects and in patients
with liver disease. In particular, papers concerning visceral aneurysms
in liver transplanted patients are very few. However, given the surge
in transplant numbers in recent years293,634 in Europe from 1968
to December 2009, i.e. about 6000 per year and just under a
thousand per year in Italy alone - the disease relevance is growing,
also because the clinical onset can be complex and dramatic.
Our analysis concerns patients with end-stage liver disease in
waiting list for LT and patients transplanted over the last 10 years,
therefore providing up-to date results.
Assuming that our findings are limited to cirrhotic patients in list
for LT, and they cannot be extended to all categories of cirrhotics,
the incidence in patients with cirrhosis was 2.6%; the female sex
was more affected in both groups.
SA was involved in 100% of cases. The multivariate analysis of
potential etiological factors indicates the importance of an
increased amylase, a beta-blocker therapy and a previous TACE.
Visceral Artery Aneurysms
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Splenic aneurysms in patients with cirrhosis were generally
asymptomatic.
The treatment of visceral aneurysms in patients with liver
disease waiting for a transplant does not always follow the classical
protocol. This is because the treatment of choice for SA
aneurysms, such as splenectomy, is a so-called ‘‘previous surgery’’
factor, and although it does not involve the hepatic hilum, it could
represent a risk factor for bleeding during the transplant; and
bleeding is a well known risk factor for survival after LT. On the
contrary, splenectomy, when performed in cirrhotics with low
platelet counts, could improve this condition, with enhanced
hemostasis.
The limited practice of SA embolization in cirrhotic patients is
caused by the possible use of this artery during the transplant to
ensure the arterial supply to the transplanted liver. So the
treatment of SA aneurysms – the only one detected in our series of
cirrhotics – consisted in standby and a ligation or a splenectomy
during the LT. In only a few cases, because of the complexity of
the transplantation involved, such treatments were not performed.
In liver transplanted patients the incidence of visceral
aneurysms and pseudoaneurysms was 1,8% and the HA was
affected in 25% of cases. In addition to the predisposition of the
female sex, there were no other statistically significant factors
related to the onset of visceral aneurysms; the arterial reconstruc-
tions during the transplant, even if followed by increased risk of
aneurysmal lesions (odds ratio 1.85), did not reach statistical
significance. Ruptures occurred in 25% of cases. Aneurysms of the
HA presented with hemobilia or liver enzyme abnormalities, and
often required complex surgical reconstruction. Severe complica-
tions occurred within 2 weeks from LT, treated with urgent
splenectomy. Not urgent patients were treated with semi-elective
ligations of the SA, whereas HA aneurysms can be risky and need
more complex arterial reconstructions, whose failure may lead to a
retransplant.
A specific issue has been the persistent patency of SA on CT
scan after proximal ligation that can be due to spleno-gastric
arteries. An option would be a splenectomy, or a proximal and
distal ligation of the SA, or the section of gastro-splenic arteries
associated with proximal ligation of the SA.
A spleen-sparing treatment of splenic aneurysms should always
be considered as splenectomy exposes to infection risks, particu-
larly in immunocompromised patients, even though published
data on the subject are scarse. On the other hand, splenectomy
may allow an early start of antiviral therapies.
Our retrospective study may have the weakness intrinsic in this
type of studies: incomplete data collection. Considering a 10-year
period has certainly reduced the problem, but the limits of this
approach are still present.
This study explores some features of LT rarely considered in
reviews.
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